Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesAnti-Malignancy Agent/Anti-VEGF Humanized Monoclonal Antibody, Avastin: Application for Approval of Additional Indication of Breast Cancer
Chugai Pharmaceutical Co., 11/09/09
Chugai Pharmaceutical Co., Ltd. announced that the company filed an application with the Japanese Ministry of Health, Labour and Welfare for the approval of an additional indication of breast cancer for the anti–malignancy agent/anti–VEGF humanized monoclonal antibody, "AVASTIN I.V. Infusion 100mg/4mL and 400mg/16mL" [generic name: bevacizumab (Recombinant) for Infusion] (hereafter, Avastin®).
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
New Targets of Therapy in T-Cell Lymphomas
Current Drug Targets, 03/22/10
Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting
Internal Medicine Journal, 03/22/10
Cetuximab combined with chemotherapy in non-small cell lung cancer
Community Oncology , 03/19/10
Article Search
Sponsor
Sponsor